This Insider Has Just Sold Shares In Mirum Pharmaceuticals

We'd be surprised if Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shareholders haven't noticed that the CEO & Director, Christopher Peetz, recently sold US$321k worth of stock at US$42.82 per share. However, the silver lining is that the sale only reduced their total holding by 2.5%, so we're hesitant to read anything much into it, on its own.

Check out our latest analysis for Mirum Pharmaceuticals

The Last 12 Months Of Insider Transactions At Mirum Pharmaceuticals

Notably, that recent sale by Christopher Peetz is the biggest insider sale of Mirum Pharmaceuticals shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$41.32. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

In total, Mirum Pharmaceuticals insiders sold more than they bought over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Insider Ownership Of Mirum Pharmaceuticals

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 1.7% of Mirum Pharmaceuticals shares, worth about US$35m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Mirum Pharmaceuticals Tell Us?

Insiders haven't bought Mirum Pharmaceuticals stock in the last three months, but there was some selling. Despite some insider buying, the longer term picture doesn't make us feel much more positive. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We'd practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Mirum Pharmaceuticals. While conducting our analysis, we found that Mirum Pharmaceuticals has 2 warning signs and it would be unwise to ignore them.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.